Grade I meningioma with disseminated bone disease: a rare clinical phenomenon

Meningioma, the second most common primary tumour of the central nervous system, is classified into three different grades based on their characteristics. Each tumour grade includes different molecular subtype, growth potential, and thus, different prognosis. Grade I meningioma is the most common subtype with a benign course, in which systemic dissemination rarely occurs. We present the case of a 48-year-old male patient with a history of grade I meningioma who was referred 3 years after the initial diagnosis to our centre due to pelvic pain. Computed tomography (CT) images showed new pelvic bone lesions whose histopathological report was compatible with a grade I meningioma. Neither hormonal therapy concomitant with octreotide nor hydroxiurea treatments were effective. Very little is known about this entity’s prevalence and treatment when disseminated disease occurs. Thus, we think it is important to increase the positive and negative clinical experiences in this setting.

[1]  M. McDermott,et al.  Meningioma metastases: incidence and proposed screening paradigm. , 2020, Journal of neurosurgery.

[2]  J. Acharya,et al.  Metastatic meningioma: Case report of a WHO grade I meningioma with liver metastases and review of the literature , 2019, Radiology case reports.

[3]  H. Abe,et al.  WHO Grade I Meningioma Metastasis to the Lung 26 Years after Initial Surgery: A Case Report and Literature Review , 2019, NMC case report journal.

[4]  Sandro Santagata,et al.  Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. , 2018, JCO precision oncology.

[5]  J. Debus,et al.  Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma , 2018, Radiation oncology.

[6]  H. Wakimoto,et al.  Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas , 2017, Oncotarget.

[7]  M. Weller,et al.  EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.

[8]  R. Zhan,et al.  Multiple pulmonary metastases in recurrent intracranial meningioma: Case report and literature review , 2016, The Journal of international medical research.

[9]  Yan Zhang,et al.  Recurrent intracranial meningioma with multiple pulmonary metastases: A case report , 2015, Oncology letters.

[10]  Z. Rappaport,et al.  Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea , 2004, Journal of Neuro-Oncology.

[11]  H. Newton,et al.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up , 2004, British journal of neurosurgery.

[12]  M. Rosenthal,et al.  Treatment of high risk or recurrent meningiomas with hydroxyurea , 2002, Journal of Clinical Neuroscience.

[13]  R. Fahlbusch,et al.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. , 1997, Journal of neurosurgery.